Murine models of acute and chronic lung infection with cystic fibrosis pathogens

International Journal of Medical Microbiology

Volumn 300, Issue 8, 2010, Pages 584-593

  Bragonzi, Alessandra ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Acute infection; Chronic infection; Cystic fibrosis; Mouse model; Pneumonia; Transgenic mice

Indexed keywords

ANTIBIOTIC AGENT; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL MODEL; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; BURKHOLDERIA CENOCEPACIA; COLONY FORMING UNIT; CYSTIC FIBROSIS; EXON; HAEMOPHILUS INFLUENZAE; HISTOPATHOLOGY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; LOBAR PNEUMONIA; LUNG FIBROSIS; LUNG INFECTION; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; PSEUDOMONAS AERUGINOSA; SHORT SURVEY; STAPHYLOCOCCUS AUREUS;

ANIMALS; BRONCHOPNEUMONIA; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; HAEMOPHILUS INFECTIONS; HUMANS; LUNG; MICE; PNEUMONIA, BACTERIAL; PNEUMONIA, STAPHYLOCOCCAL; PSEUDOMONAS INFECTIONS;

EID: 78549239179     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2010.08.012     Document Type: Short Survey

References (86)

1. Allewelt M., Coleman F.T., Grout M., Priebe G.P., Pier G.B. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect. Immun. 2000, 68:3998-4004.
2. Beaulac C., Clément-Major S., Hawari J., Lagacé J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob. Agents Chemother. 1996, 40:665-669.
3. Beaulac C., Sachetelli S., Lagacé J. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J. Drug Target. 1999, 7:33-41.
4. Bedrossian C.W., Greenberg S.D., Singer D.B., Hansen J.J., Rosenberg H.S. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum. Pathol. 1976, 7:195-204.
5. Bernier S.P., Silo-Suh L., Woods D.E., Ohman D.E., Sokol P.A. Comparative analysis of plant and animal models for characterization of Burkholderia cepacia virulence. Infect. Immun. 2003, 71:5306-5313.
6. Boucher J.C., Yu H., Mudd M.H., Deretic V. Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect. Immun. 1997, 65:3838-3846.
7. Bragonzi A., Wiehlmann L., Klockgether J., Cramer N., Worlitzsch D., Döring G., Tümmler B. Sequence diversity of the mucABD locus in Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Microbiology 2006, 152:3261-3269.
8. Bragonzi A., Paroni M., Nonis A., Cramer N., Montanari S., Rejman J., Di Serio C., Döring G., Tümmler B. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am. J. Respir. Crit. Care Med. 2009, 180:138-145.
9. Bragonzi A., Worlitzsch D., Pier G.B., Timpert P., Ulrich M., Hentzer M., Andersen J.B., Givskov M., Conese M., Döring G. Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J. Infect. Dis. 2005, 192:410-419.
10. Bryant C.D., Zhang N.N., Sokoloff G., Fanselow M.S., Ennes H.S., Palmer A.A., McRoberts J.A. Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies. J. Neurogenet. 2008, 22:315-331.
11. Campbell P.W., Phillips J.A. The cystic fibrosis gene and relationships to clinical status. Semin. Respir. Infect. 1992, 7:150-157.
12. Cash H.A., Woods D.E., McCullough B., Johanson W.G., Bass J.A. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 1979, 119:453-459.
13. Cheung A.T., Moss R.B., Kurland G., Leong A.B., Novick W.J. Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys. II. A histopathologic analysis. J. Med. Primatol. 1993, 22:257-262.
14. Cheung A.T., Moss R.B., Leong A.B., Novick W.J. Chronic Pseudomonas aeruginosa endobronchitis in rhesus monkeys. I. Effects of pentoxifylline on neutrophil influx. J. Med. Primatol. 1992, 21:357-362.
15. Chroneos Z.C., Wert S.E., Livingston J.L., Hassett D.J., Whitsett J.A. Role of cystic fibrosis transmembrane conductance regulator in pulmonary clearance of Pseudomonas aeruginosa in vivo. J. Immunol. 2000, 165:3941-3950.
16. Colledge W.H., Abella B.S., Southern K.W., Ratcliff R., Jiang C., Cheng S.H., MacVinish L.J., Anderson J.R., Cuthbert A.W., Evans M.J. Generation and characterization of a delta F508 cystic fibrosis mouse model. Nat. Genet. 1995, 10:445-452.
17. Comolli J.C., Hauser A.R., Waite L., Whitchurch C.B., Mattick J.S., Engel J.N. Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia. Infect. Immun. 1999, 67:3625-3630.
18. Cook M.N., Bolivar V.J., McFadyen M.P., Flaherty L. Behavioral differences among 129 substrains: implications for knockout and transgenic mice. Behav. Neurosci. 2002, 116:600-611.
19. Cressman V.L., Hicks E.M., Funkhouser W.K., Backlund D.C., Koller B.H. The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice. Am. J. Respir. Cell Mol. Biol. 1998, 19:853-866.
20. Davidson D.J., Dorin J.R., McLachlan G., Ranaldi V., Lamb D., Doherty C., Govan J., Porteous D.J. Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens. Nat. Genet. 1995, 9:351-357.
21. Delaney S.J., Alton E.W., Smith S.N., Lunn D.P., Farley R., Lovelock P.K., Thomson S.A., Hume D.A., Lamb D., Porteous D.J., Dorin J.R., Wainwright B.J. Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO J. 1996, 15:955-963.
22. Dickinson P., Kimber W.L., Kilanowski F.M., Webb S., Stevenson B.J., Porteous D.J., Dorin J.R. Enhancing the efficiency of introducing precise mutations into the mouse genome by hit and run gene targeting. Transgenic Res. 2000, 9:55-66.
23. Dorin J.R., Dickinson P., Alton E.W., Smith S.N., Geddes D.M., Stevenson B.J., Kimber W.L., Fleming S., Clarke A.R., Hooper M.L., Anderson L., Beddington R.S.P., Porteous D.J.N. Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature 1992, 359:211-215.
24. Duncan W.Borthwick, West J.D.W., Margaret A., Keighren J.H.Flockhart, Brendan A.Innes, Julia R.Dorin Murine submucosal glands are clonally derived and show a cystic fibrosis gene-dependent distribution pattern. Am. J. Respir. Cell Mol. Biol. 1999, 20:1181-1189.
25. Durie P.R., Kent G., Phillips M.J., Ackerley C.A. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am. J. Pathol. 2004, 164:1481-1493.
26. Ellsworth R.E., Jamison D.C., Touchman J.W., Chissoe S.L., Braden Maduro V.V., Bouffard G.G., Dietrich N.L., Beckstrom-Sternberg S.M., Iyer L.M., Weintraub L.A., Cotton M., Courtney L., Edwards J., Maupin R., Ozersky P., Rohlfing T., Wohldmann P., Miner T., Kemp K., Kramer J., Korf I., Pepin K., Antonacci-Fulton L., Fulton R.S., Minx P., Hillier L.W., Wilson R.K., Waterston R.H., Miller W., Green E.D. Comparative genomic sequence analysis of the human and mouse cystic fibrosis transmembrane conductance regulator genes. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1172-1177.
27. Gerlai R. Gene-targeting studies of mammalian behavior. Is it the mutation or the background genotype?. Trends Neurosci. 1996, 19:177-181.
28. Gosselin D., Stevenson M.M., Cowley E.A., Griesenbach U., Eidelman D.H., Boule M., Tam M.F., Kent G., Skamene B., Tsui L.C., Radzioch D. Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa. AJRCCM 1998, 157:1253-1262.
29. Govan J.R., Fyfe J.A., Baker N.R. Heterogeneity and reduction in pulmonary clearance of mucoid Pseudomonas aeruginosa. Rev. Infect. Dis. 1983, 5:S874-S879.
30. Grubb B.R., Paradiso A.M., Boucher R.C. Anomalies in ion transport in cf mouse tracheal epithelium. Am. J. Physiol. 1994, 267:293-300.
31. Grubb B.R., Pickles R.J., Ye H., Yankaskas J.R., Vick R.N., Engelhardt J.F., Wilson J.M., Boucher R.C. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994, 1994:802-806.
32. Hasty P., O'Neal W.K., Liu K.Q., Morris A.P., Bebok Z., Shumyatsky G.B., Jilling T., Sorscher E.J., Bradley A., Beaudet A.L. Severe phenotype in mice with termination mutation in exon 2 of cystic fibrosis gene. Somat. Cell Mol. Genet. 1995, 21:177-187.
33. Hoffmann N., Lee B., Hentzer M., Rasmussen T.B., Song Z., Johansen H.K., Givskov M., Høiby N. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic Pseudomonas aeruginosa lung infection in Cftr(-/-) mice. Antimicrob. Agents Chemother. 2007, 51:3677-3687.
34. Hoffmann N., Rasmussen T.B., Jensen P.O., Stub C., Hentzer M., Molin S., Ciofu O., Givskov M., Johansen H.K., Høiby N. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect. Immun. 2005, 73:2504-2514.
35. Jackson A.E., Southern P.M., Pierce A.K., Fallis B.D., Sanford J.P. Pulmonary clearance of gram-negative bacilli. J. Lab. Clin. Med. 1967, 69:833-841.
36. Johansen H.K., Hougen H.P., Cryz S.J., Rygaard J., Høiby N. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Am. J. Respir. Crit. Care Med. 1995, 152:1337-1346.
37. Kemmerich B., Small G.J., Pennington J.E. Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia. Antimicrob. Agents Chemother. 1986, 29:395-399.
38. Kent G., Lles R., Bear C.E., Huan L.-J., Griesenbach U., McKerlie C., Frndova H., Ackerley C., Gosselin D., Radzioch D., O'Brodovich H., Tsui L.-C., Buchwald M., Tanswell A.K. Lung disease in mice with cystic fibrosis. J. Clin. Invest. 1997, 100:3060-3069.
39. Konstan M.W., Butler S.M., Wohl M.E., Stoddard M., Matousek R., Wagener J.S., Johnson C.A., Morgan W.J. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J. Pediatr. 2003, 142:624-630.
40. Konstan M.W., Vargo K.M., Davis P.B. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am. Rev. Respir. Dis. 1990, 141:186-192.
41. - channels expressed in mammalian cells. J. Physiol. 1998, 508:379-392.
42. Lathe R. Mice, gene targeting and behaviour: more than just genetic background. Trends Neurosci. 1996, 19:183-186.
43. Lee V.T., Smith R.S., Tümmler B., Lory S. Activities of Pseudomonas aeruginosa effectors secreted by the type III secretion system in vitro and during infection. Infect. Immun. 2005, 73:1695-1705.
44. Maciver I., Silverman S.H., Brown M.R., O'Reilly T. Rat model of chronic lung infections caused by non-typable Haemophilus influenzae. J. Med. Microbiol. 1991, 35:139-147.
45. + absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 2004, 10:487.
46. + channel-overexpressing mice. Am. J. Respir. Crit. Care Med. 2008, 177:730-742.
47. McCray P.B., Zabner J., Jia H.P., Welsh M.J., Thorne P.S. Efficient killing of inhaled bacteria in DeltaF508 mice: role of airway surface liquid composition. Am. J. Physiol. 1999, 277:L183-L190.
48. McMorran B.J., Zabner J., Lunn D.P., Oceandy D., Costelloe E.O., Thomas G.R., Hume D.A., Wainwright B.J. G551D CF mice display an abnormal host response and have impaired clearance of Pseudomonas lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:740-747.
49. Mekada K., Abe K., Murakami A., Nakamura S., Nakata H., Moriwaki K., Obata Y., Yoshiki A. Genetic differences among C57BL/6 substrains. Exp. Anim. 2009, 58:141-149.
50. Montaguelli X. Effect of the genetic background on the phenotype of mouse mutations. J. Am. Soc. Nephrol. 2000, 11:S101-S105.
51. Montanari S., Oliver A., Salerno P., Mena A., Bertoni G., Tümmler B., Cariani L., Conese M., Döring G., Bragonzi A. Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 2007, 153:1445-1454.
52. Morissette C., Skamene E., Gervais F. Endobronchial inflammation following Pseudomonas aeruginosa infection in resistant and susceptible strains of mice. Infect. Immun. 1995, 63:1718-1724.
53. Moser C., Van Gennip M., Bjarnsholt T., Jensen P.Ø., Lee B., Hougen H.P., Calum H., Ciofu O., Givskov M., Molin S., Høiby N. Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. APMIS 2009, 117:95-107.
54. O'Neal W.K., Hasty P., McCray P.B., Casey B., Rivera-Pérez J., Welsh M.J., Beaudet A.L., Bradley A. A severe phenotype in mice with a duplication of exon 3 in the cystic fibrosis locus. Hum. Mol. Genet. 1993, 2:1561-1569.
55. Pedersen S.S., Shand G.H., Hansen B.L., Hansen G.N. Induction of experimental chronic Pseudomonas aeruginosa lung infection with Pseudomonas aeruginosa entrapped in alginate microspheres. APMIS 1990, 98:203-211.
56. Pier G.B., Small G.J., Warren H.B. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 1990, 249:537-540.
57. Pirone L., Bragonzi A., Farcomeni A., Paroni M., Auriche C., Conese M., Chiarini L., Dalmastri C., Bevivino A., Ascenzioni F. Burkholderia cenocepacia strains isolated from cystic fibrosis patients are apparently more invasive and more virulent than rhizosphere strains. Environ. Microbiol. 2008, 10:2773-2784.
58. Ratcliff R., Evans M.J., Cuthbert A.W., MacVinish L.J., Foster D., Anderson J.R., Colledge W.H. Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat. Genet. 1993, 4:35-41.
59. Riedel K., Hentzer M., Geisenberger O., Huber B., Steidle A., Wu H., Høiby N., Givskov M., Molin S., Eberl L. N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology 2001, 147:3249-3262.
60. Rozmahel R., Wilschanski M., Matin A., Plyte S., Oliver M., Auerbach W., Moore A., Forstner J., Durie P., Nadeau J., Bear C., Tsui L.C. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat. Genet. 1996, 12:280-287.
61. Sajjan U., Thanassoulis G., Cherapanov V., Lu A., Sjolin C., Steer B., Wu Y.J., Rotstein O.D., Kent G., McKerlie C., Forstner J., Downey G.P. Enhanced susceptibility to pulmonary infection with Burkholderia cepacia in Cftr(-/-) mice. Infect. Immun. 2001, 69:5138-5150.
62. Sapru K., Stotland P.K., Stevenson M.M. Quantitative and qualitative differences in bronchoalveolar inflammatory cells in Pseudomonas aeruginosa-resistant and -susceptible mice. Clin. Exp. Immunol. 1999, 115:103-109.
63. Schroeder T.H., Reiniger N., Meluleni G., Grout M., Coleman F.T., Pier G.B. Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. J. Immunol. 2001, 166:7410-7418.
64. Shaver C.M., Hauser A.R. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect. Immun. 2004, 72:6969-6977.
65. Simpson E.M., Linder C.C., Sargent E.E., Davisson M.T., Mobraaten L.E., Sharp J.J. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nat. Genet. 1997, 16:19-27.
66. Snouwaert J.N., Brigman K.K., Latour A.M., Malouf N.N., Boucher R.C., Smithies O., Koller B.H. An animal model for cystic fibrosis made by gene targeting. Science 1992, 257:1083-1088.
67. Southern P.M., Mays B.B., Pierce A.K., Sanford J.P. Pulmonary clearance of Pseudomonas aeruginosa. J. Lab. Clin. Med. 1970, 76:548-559.
68. Starke J.R., Edwards M.S., Langston C., Baker C.J. A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr. Res. 1987, 22:698-702.
69. Tam M., Snipes G.J., Stevenson M.M. Characterization of chronic bronchopulmonary Pseudomonas aeruginosa infection in resistant and susceptible inbred mouse strains. Am. J. Respir. Cell Mol. Biol. 1999, 20:710-719.
70. Tang H.B., DiMango E., Bryan R., Gambello M., Iglewski B.H., Goldberg J.B., Prince A. Contribution of specific Pseudomonas aeruginosa virulence factors to pathogenesis of pneumonia in a neonatal mouse model of infection. Infect. Immun. 1996, 64:37-43.
71. Thomassen M.J., Klinger J.D., Winnie G.B., Wood R.E., Burtner C., Tomashefski J.F., Horowitz J.G., Tandler B. Pulmonary cellular response to chronic irritation and chronic Pseudomonas aeruginosa pneumonia in cats. Infect. Immun. 1984, 45:741-747.
72. Threadgill D.W., Yee D., Matin A., Nadeau J.H., Magnuson T. Genealogy of the 129 inbred strains: 129/SvJ is a contaminated inbred strain. Mamm. Genome 1997, 8:390-393.
73. van Doorninck J.H., French P.J., Verbeek E., Peters R.H., Morreau H., Bijman J., Scholte B.J. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J. 1995, 14:4403-4411.
74. van Heeckeren A., Walenga R., Konstan M.W., Bonfield T., Davis P.B., Ferkol T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J. Clin. Invest. 1997, 100:2810-2815.
75. van Heeckeren A.M., Tscheikuna J., Walenga R.W., Konstan M.W., Davis P.B., Erokwu B., Haxhiu M.A., Ferkol T.W. Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. Am. J. Respir. Crit. Care Med. 2000, 161:271-279.
76. van Heeckeren A.M., Schluchter M.D. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab. Anim. 2002, 36:291-312.
77. van Heeckeren A.M., Schluchter M.D., Drumm M.L., Davis P.B. Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287:944-952.
78. van Heeckeren A.M., Schluchter M.D., Xue L., Alvarez J., Freedman S., St George J., Davis P.B. Nutritional effects on host response to lung infections with mucoid Pseudomonas aeruginosa in mice. Infect. Immun. 2004, 72:1479-1486.
79. van Heeckeren A.M., Schluchter M.D., Xue W., Davis P.B. Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice. Am. J. Respir. Crit. Care Med. 2006, 173:288-296.
80. Winnie G.B., Klinger J.D., Sherman J.M., Thomassen M.J. Induction of phagocytic inhibitory activity in cats with chronic Pseudomonas aeruginosa pulmonary infection. Infect. Immun. 1982, 38:1088-1093.
81. Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K.C., Birrer P., Bellon G., Berger J., Weiss T., Botzenhart K., Yankaskas J.R., Randell S., Boucher R.C., Döring G. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002, 109:317-325.
82. Wu H., Song Z., Givskov M., Döring G., Worlitzsch D., Mathee K., Rygaard J., Høiby N. Pseudomonas aeruginosa mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology 2001, 147:1105-1113.
83. Yu H., Hanes M., Chrisp C.E., Boucher J.C., Deretic V. Microbial pathogenesis in cystic fibrosis: pulmonary clearance of mucoid Pseudomonas aeruginosa and inflammation in a mouse model of repeated respiratory challenge. Infect. Immun. 1998, 66:280-288.
84. Yu H., Nasr S.Z., Deretic V. Innate lung defenses and compromised Pseudomonas aeruginosa clearance in the malnourished mouse model of respiratory infections in cystic fibrosis. Infect. Immun. 2000, 68:2142-2147.
85. Zeiher B.G., Eichwald E., Zabner J., Smith J.J., Puga A.P., McCray P.B., Capecchi M.R., Welsh M.J., Thomas K.R. A mouse model for the delta F508 allele of cystic fibrosis. J. Clin. Invest. 1995, 96:2051-2064.
86. Zhou L., Dey C.R., Wert S.E., DuVall M.D., Frizzell R.A., Whitsett J.A. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 1994, 266:1705-1708.